Nyxoah S.A. is a Belgian medical device company, focused on developing and commercializing a disruptive neurostimulation based therapy for the treatment of Obstructive Sleep Apnea (OSA).
In Western countries alone there are 5 million moderate to severe OSA patients who require treatment but have failed the current gold standard, Continuous Positive Airway Pressure (CPAP) therapy, which requires a bulky machine and wearing a mask at night. Neurostimulation is an effective and well-established therapy for OSA that can address this unmet need.
Nyxoah has developed the first and only lead-free neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe OSA patients. The implanted battery-free stimulator only requires a small incision. It is externally powered by an activation chip, connected to a disposable patch, which is positioned on the patient's chin at night.